Issues
-
Cover Image
Cover Image
Antibodies against epithelial cell adhesion molecule (EpCAM) and cytokeratins are commonly used to capture and detect circulating tumor cells (CTC). However, these approaches are potentially hampered by the fact that migratory cancer cells may undergo a process called the epithelial-mesenchymal transition that is characterized by downregulation of epithelial markers, including cytokeratins and EpCAM. Images are of EpCAM(−)/CD45(−) circulating tumor cells immunostained with antibodies against cytokeratin (red, top), PLS3 (green, middle), and vimentin (orange, bottom). All sections were counterstained with DAPI (blue). PLS3 was expressed on EpCAM(−) CTCs that displayed reduced cytokeratin staining, accompanied by strong staining for vimentin. For details, see article by Yokobori and colleagues on page 2059. - PDF Icon PDF LinkTable of Contents
Cancer Research
Table of Contents
Breaking Advances
Reviews
Priority Reports
Differential Contributions of STAT5A and STAT5B to Stress Protection and Tyrosine Kinase Inhibitor Resistance of Chronic Myeloid Leukemia Stem/Progenitor Cells
Clinical Studies
Plastin3 Is a Novel Marker for Circulating Tumor Cells Undergoing the Epithelial–Mesenchymal Transition and Is Associated with Colorectal Cancer Prognosis
Integrated Systems and Technologies
Microenvironment and Immunology
Molecular and Cellular Pathobiology
Prevention and Epidemiology
Common Genetic Polymorphisms Modify the Effect of Smoking on Absolute Risk of Bladder Cancer
Therapeutics, Targets, and Chemical Biology
Erlotinib Prolongs Survival in Pancreatic Cancer by Blocking Gemcitabine-Induced MAPK Signals
Targeting the Deregulated Spliceosome Core Machinery in Cancer Cells Triggers mTOR Blockade and Autophagy
Cisplatin Resistance Associated with PARP Hyperactivation
Tumor and Stem Cell Biology
A CD90+ Tumor-Initiating Cell Population with an Aggressive Signature and Metastatic Capacity in Esophageal Cancer
Sirtuin-1 Regulates Acinar-to-Ductal Metaplasia and Supports Cancer Cell Viability in Pancreatic Cancer
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.